When are steroids indicated for chronic obstructive pulmonary disease (COPD)?

When Steroids Are Indicated for COPD

Systemic corticosteroids are indicated for acute COPD exacerbations (moderate to severe), where they improve lung function, oxygenation, and shorten recovery time and hospitalization duration. 1

Acute Exacerbations (Systemic Steroids)

For any acute COPD exacerbation requiring treatment beyond short-acting bronchodilators alone, give systemic corticosteroids (oral or IV) immediately. 2 This includes:

• Moderate exacerbations: Treated with bronchodilators + antibiotics and/or oral corticosteroids
• Severe exacerbations: Requiring hospitalization or emergency department visit

Key Treatment Parameters:

• Duration: 5-7 days is sufficient (no benefit beyond this) 3
• Route: Oral or intravenous (equally effective)
• Benefit window: Reduces recurrent exacerbations only in the first 30 days following the initial exacerbation 2
• Do NOT continue systemic steroids beyond 30 days for exacerbation prevention (Grade 1A recommendation) 2

The evidence is clear that systemic corticosteroids improve FEV1, oxygenation, and reduce recovery time during acute exacerbations 1. A large study confirmed that 5 days is non-inferior to 14 days of treatment 3, allowing us to minimize cumulative steroid exposure and associated risks (hyperglycemia, weight gain, insomnia, osteoporosis, adrenal suppression).

Stable COPD (Inhaled Corticosteroids)

Inhaled corticosteroids should be reserved for patients with:

1. Severe COPD (FEV1 <60% predicted) AND
2. Frequent exacerbations (≥1 moderate-to-severe exacerbation in the previous year despite optimal bronchodilator therapy) 2

Treatment Algorithm for Stable COPD:

Step 1: Start with short-acting bronchodilators (β2-agonists ± anticholinergics)

Step 2: Add long-acting bronchodilators:

• Long-acting muscarinic antagonist (LAMA) monotherapy, OR
• LAMA/LABA combination
• These are the foundation of COPD treatment 2

Step 3: Consider adding ICS only if:

• Patient continues to have ≥1 exacerbation per year despite optimal bronchodilator therapy
• FEV1 <60% predicted
• Consider blood eosinophil count (higher counts may predict better ICS response) 4, 5

Critical Caveats:

Do NOT use ICS monotherapy - always combine with long-acting bronchodilators 2

ICS increase pneumonia risk - this is a real concern, though the absolute excess risk is approximately 0-3% above baseline 6. The benefits must outweigh this risk, which occurs primarily in patients with frequent exacerbations and severe disease.

Deprescribing ICS is safe in stable patients with:

• Infrequent exacerbations
• Mild-to-moderate COPD
• Lower eosinophil counts 7

Common Pitfalls to Avoid:

1. Over-prescribing ICS: Up to 75% of COPD patients receive ICS, but only ~20% have severe disease warranting them 8. Many patients receive ICS as first-line therapy inappropriately.

2. Continuing systemic steroids long-term: No evidence supports this beyond 30 days post-exacerbation, and risks far outweigh benefits 2

3. Using longer courses during exacerbations: 5-7 days is sufficient; 10-14 days adds no benefit 3

4. Ignoring the eosinophilic phenotype: Patients with elevated blood eosinophils may derive greater benefit from ICS 4, 5